Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. (4th May 2023)

• Record Type: Journal Article
• Authors: Baccelli, Andrea; Koćwin, Marcelina; Parazzini, Elena M.; Rinaldo, Rocco F.; Centanni, Stefano
• Is Part Of: Journal of asthma. Volume 60:Number 5(2023)
• Page Start: 1050
• Page End: 1053
• Publication Date: 2023-05-04
• Subjects: Severe asthma -- biologic therapy -- eosinophilic asthma -- allergic asthma -- uncontrolled asthma; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2022.2109162
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Introduction: Treatment with biologics has significantly reduced the social and economic burden of severe asthma. However, some patients may still feature a suboptimal control of their symptoms while on therapy. In this subset of asthmatic patients, a benefit from a dual biologic therapy has sporadically been reported in literature. Our aim is to add our experience to the limited body of evidence supporting combination biologic therapies. Case study: Here we present the case of a 68-year-old nonsmoker female, with an allergic and eosinophilic corticosteroid-dependent severe asthma. She displayed well controlled comorbidities and good adherence to the inhaled therapy. Omalizumab was started in 2008 with an initial remarkable clinical improvement. After nine years of biologic therapy, she reported a gradual worsening of her symptoms and exacerbations. Mepolizumab was then added in 2019. Results: The addition of Mepolizumab resulted in a meaningful amelioration of her quality of life, asthma control, number of exacerbations and 6-minute-walking-distance at 3-year follow-up. The average Prednisone dosage was tapered from 25 mg to 20 mg daily. No adverse events were observed since the introduction of the second biologic. Conclusion: Our experience indicates that Mepolizumab may be beneficial and safe as an add-on biologic in a patient whose allergic and eosinophilic asthma remains uncontrolled despite treatment with an anti-IgE strategy. Further studies on a larger number of patients are required to demonstrate whether the positive outcomes published so far are replicable on a larger scale.